AIM AIM ImmunoTech Inc.
Price Chart
Executive Summary
AIM ImmunoTech is pricing a ~$2.44M best-efforts public offering of 7,519,351 shares at $0.325/share (20.7% discount to the $0.41 close), coupled with a concurrent private placement of warrants for 15,038,702 additional shares at the same strike. The offering comes two days after an 8-K revealed a $1.68M debt extension and a Q1 EPS miss, and the company remains non-compliant with NYSE American listing standards. Proceeds of ~$2.2M are earmarked for a Phase 3 pancreatic cancer trial and working capital, but the massive dilution (~46% share increase plus warrant overhang) and distressed context make this a clear bearish event.
Actionable Insight
Expect significant downward pressure from the 20.7% discount pricing and massive dilution. The warrant overhang (15M shares at $0.325) will cap any upside until exercised or expired. Monitor for stockholder approval vote (deadline July 21, 2026) and the NYSE American compliance deadline (June 11, 2026). The company's cash runway is extended to ~12 months per management, but the best-efforts structure means actual proceeds could be lower.
Key Facts
- Offering 7,519,351 shares at $0.325/share, a 20.7% discount to the $0.41 prior close
- Concurrent private placement of Series I warrants for 15,038,702 shares at $0.325 strike, exercisable upon stockholder approval for 5 years
- Shares outstanding will increase from 16,505,501 to 24,024,852 post-offering, a 45.6% dilution
- Net proceeds estimated at ~$2.2M; no minimum offering amount required
- Company is not in compliance with NYSE American's $6M stockholders' equity rule; had a $9.8M deficit as of Dec 31, 2025
- Q1 2026 EPS miss of $-0.57 vs $-0.37 consensus reported in the May 19 8-K
- Streeterville Capital note extended to June 2027 with $1.68M outstanding; third consecutive amendment signals financial distress
- Placement agent fees total 8.75% of gross proceeds plus $100K expense reimbursement and 451,161 warrants at $0.40625
Financial Impact
~$2.44M gross / ~$2.2M net proceeds; 45.6% immediate dilution; $0.17/share dilution to new investors; warrant overhang of 15M+ shares
Risk Factors
- NYSE American delisting risk if stockholders' equity not restored to $6M by June 11, 2026
- Best-efforts offering may raise less than $2.2M, jeopardizing Phase 3 trial funding
- Warrant exercise could add 15M+ shares, further diluting existing holders
- Deep operating losses and third consecutive debt amendment signal potential going-concern risk
- Stock price could fall below $0.10, triggering NYSE American low-price delisting rule
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-024759 |
| Document: 0001493152-26-024759-index-headers.html | 0001493152-26-024759 |
| Document: 0001493152-26-024759-index.html | 0001493152-26-024759 |
| Document: 0001493152-26-024759.txt | 0001493152-26-024759 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
1d ago
|
Press Release
| $0.4589 awaiting T+1 | awaiting T+1 | — | $0.5200 (+13.31%) |
|
Jun 4, 2026
5d ago
|
8-K
| $0.5900 $0.5200 | ▼ −11.86% | ▼ −9.27% | $0.5200 (−11.86%) |
|
Jun 1, 2026
8d ago
|
Press Release
| $0.9000 $0.8300 | ▼ −7.78% | ▼ −7.92% | $0.5200 (−42.22%) |
|
May 21, 2026
19d ago
|
8-K
| $0.2400 $0.2400 | · 0.00% | ▲ +0.45% | $0.5200 (−116.67%) |
|
May 21, 2026
19d ago
|
424B5
| $0.2400 $0.2400 | · 0.00% | ▲ +0.45% | $0.5200 (−116.67%) |
|
May 20, 2026
20d ago
|
Press Release
| $0.2500 $0.2400 | ▲ +4.00% | ▲ +4.19% | $0.5200 (−108.00%) |
|
May 19, 2026
21d ago
|
424B5
| $0.2500 $0.2400 | ▼ −4.00% | ▼ −4.19% | $0.5200 (+108.00%) |
|
May 19, 2026
21d ago
|
8-K
| $0.4100 $0.2500 | ▼ −39.02% | ▼ −40.06% | $0.5200 (+26.83%) |
|
May 14, 2026
26d ago
|
8-K
| $0.2600 $0.2500 | ▼ −3.85% | ▼ −2.62% | $0.5200 (+100.00%) |
|
May 14, 2026
26d ago
|
Press Release
| $0.2600 $0.2500 | ▼ −3.85% | ▼ −2.62% | $0.5200 (+100.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access